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HELMINTH DEFENCE MOLECULES
(HDMs)—ANTIMICROBIALS OR
IMMUNOMODULATORS?
Parasitic helminths (worms) are one of the
most successful animal groups in nature.
They are large multicellular organisms and
therefore cannot penetrate host cells but
must reside inside tissue or organs. They
infect over 1 billion people globally, mostly
in tropical/sub-tropical regions, taking an
enormous toll on animal and human
health (Hotez et al., 2008). Although the
main evolutionary driving force for para-
sitism may have been the ease of access to
food this brought other challenges, most
importantly the need to overcome expul-
sion by the immune responses of the host.
Accordingly, helminths have evolved elab-
orate mechanisms to manage, suppress
or manipulate the mammalian immune
system.
It is generally thought that worms influ-
ence the host immune response by secret-
ing factors into their environment—the
host parasite interface. Over the past 10
years the application of proteomics tech-
niques has allowed us to identify molecules
secreted by helminths. Although the exact
complement of secretory molecules dif-
fers between species, most helminths
release proteolytic enzymes with endo-
and exo-peptidase activities (Robinson
et al., 2008a,b), antioxidants such as
glutathione-S transferase and peroxire-
doxin (Jefferies et al., 2001; Donnelly et al.,
2008; Robinson et al., 2009) and other
molecules with a range of biochemical
activities including protease inhibitors and
metabolic enzymes. Whilst the biological
function of a few of these helminth
molecules are well defined, this is generally
restricted to those that possess evolution-
arily conserved catalytic domains/active
site residues that are easily identified using
bioinformatics search tools (e.g., Fasciola
cysteine proteases function in fluke nutri-
tion; Lowther et al., 2009). However, many
helminths also secrete a range of molecules
whose primary sequences offer no clue as
to their biochemical activity or biological
function.
During our on-going analysis of the
secretory proteome (i.e., the secretome) of
the helminth Fasciola hepatica, a parasite
that infects its host via the intestine fol-
lowing ingestion and then migrates to the
liver, we identified a novel and abundant
8 kDa protein. The protein contained a
secretory signal peptide but BLAST anal-
ysis of its primary sequence failed to infer
a function. However, structural studies
revealed that a 37 amino acid C-terminal
region adopted a similar secondary struc-
ture (amphipathic α-helix) to a number of
peptides with known antimicrobial and/or
immunomodulatory functions, most par-
ticularly mammalian LL-37 (Robinson
et al., 2011). Phylogenetic analysis dis-
covered that these secretory proteins
are conserved across the major trema-
tode species that collectively infect >1
billion humans, including the liver
flukes Clonorchis sinensis, Paragonimus
westermani, and Opisthorchis viver-
rini and the blood flukes Schistosoma
mansoni and S. japonicum (Robinson
et al., 2011). Accordingly, by anal-
ogy with the mammalian antimicrobial
and/or immunomodulators we hypoth-
esized that these helminth molecules
may play a critical role in the para-
sites interaction with its host and thus
named them helminth defence molecules
(HDMs). This hypothesis, however, posed
the question that is central to under-
standing how they may perform this
function, namely, are HDMs antimicro-
bial or immunomodulatory peptides,
or both?
HDMs DO NOT POSSESS
ANTIMICROBIAL OR HAEMOLYTIC
ACTIVITY
To begin to address this question,
we compared the ability of helminth-
derived HDMs with several well-known
mammalian host-derived antimicrobial
peptides [AMPs; also termed host defence
peptides (HDPs) where they display
immunomodulatory activities] to directly
kill clinically-relevant microorganisms
(Thivierge et al., 2013). The antimicro-
bial effect of AMPs/HDPs is attributed to
the ability of their amphipathic helices to
bind, and thus disrupt, negatively charged
bacterial cell membranes (Hancock
and Chapple, 1999). Despite having
similar biochemical/biophysical prop-
erties to the host-derived AMPs/HDPs
including LL-37, CRAMP, SMAP-29,
and BMAP-28 which variously showed
activity against both gram-negative
(Escherichia coli, Pseudomonas aerugi-
nosa, and Salmonella typhimurium) and
gram-positive (Staphylococcus epidermis
and Staphylococcus aureus) bacteria,
none of the HDMs tested demonstrated
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bactericidal activity against any species
of bacteria at the concentrations tested
(<0.25–128μg/ml; Thivierge et al., 2013).
Previous studies had also shown
that AMPs/HDPs are cytotoxic to kine-
toplastid protozoan parasites such as
Leishmania major (Lynn et al., 2011),
Trypanosoma cruzi (Haines et al., 2009),
and the apicomplexan protozoan para-
sites Cryptosporidium sp. (Carryn et al.,
2012). In our studies, whilst we confirmed
that several vertebrate AMPs/HDPs killed
the apicomplexan protozoan parasite
Cryptosporidium parvum and C. homi-
nis in vitro at concentrations as low as
0.025μM none of the HDMs tested dis-
played any parasiticidal activity even at
2.5μM (Thivierge et al., 2013).
The predominant mechanism of
AMP/HDP bactericidal activity is the
formation of pores in the membrane
lipid bilayer, destroying its integrity
and causing cell death (Oren and Shai,
1998). However, this effect is not spe-
cific to bacterial cells since eukaryotic
cells can also be lysed via this mech-
anism (Ciornei et al., 2005). Whilst
the mammalian AMPs/HDPs rapidly
lysed red blood cells in a concentration-
dependent manner (from 8 to 256μg/ml),
the HDMs did not induce signifi-
cant lysis at equivalent concentrations
(Thivierge et al., 2013). Using a fluorescent
membrane-impermeant dye we demon-
strated that the mammalian peptides
LL-37, CRAMP, SMAP-29, and BMAP-28
(50μM) induced the formation of pores
in a murine macrophage cell line and in
general, were cytotoxic at concentrations
of >25μM. However, at the same con-
centrations none of the helminth peptides
exhibited these lytic or cytotoxic effects
(Thivierge et al., 2013).
The contrasting effects of the mam-
malian AMPs/HDPs and the helminth
HDMs may be due to the targeting
of specific membrane components by
HDMs necessary for internalization into
host cells rather than non-specific “car-
pet” binding to the phospholipid bilayer
that may occur with the AMPs/HDPs
(Brender et al., 2012). We have shown
that F. hepatica HDM (FhHDM-1) binds
to host macrophage plasma membrane
lipid rafts, possibly via selective interac-
tion with cholesterol, before being inter-
nalized by endocytosis (Robinson et al.,
2012). In contrast, human LL-37 cannot
bind to cholesterol; indeed its presence
strongly reduces the ability of LL-37 to
interact with phospholipid membranes
(Sood and Kinnunen, 2008). Whilst the
precise mechanism(s) governing the selec-
tivity of the HDMs vs. AMPs/HDPs is
not fully understood, our observations
show that, rather than simply destroy-
ing host cells by lysis, HDMs have
evolved specifically to interact with host
cell membranes without causing their
disruption.
HDMs DISPLAY A VARIETY OF
IMMUNOMODULATORY ACTIVITIES
Parasitic helminths secrete a range of sol-
uble effector molecules that modulate
host immune responses in a myriad
of ways to establish an environment
that facilitates their survival and a pro-
longed reproductive phase (reviewed by
Harnett and Harnett, 2010). We have
previously shown that F. hepatica and
S. mansoni secrete molecules with specific
immunomodulatory functions: peroxire-
doxin (Prx) promotes the development of
host Th2 responses via the induction of
M2 macrophages (Donnelly et al., 2005,
2008) and cathepsin L1 (FhCL1) inhibits
the macrophage MyD88-independant,
TRIF-dependant signaling pathway via
cleavage of toll-like receptor (TLR) 3
within the endosome (Donnelly et al.,
2010). However, our recent studies have
shown that HDMs are “utility play-
ers” in the host-parasite interaction and
exert multiple effects on host immune
cells.
In order to infect their mammalian
host, the infective stage of F. hepatica,
termed newly excysted juveniles (NEJs),
secrete an array of cysteine peptidases
including cathepsins B and cathep-
sins L that digest a path through the
intestinal wall (McGonigle et al., 2008;
Robinson et al., 2009). Despite this
loss of barrier function of the intestinal
epithelium and consequent translo-
cation of luminal antigens (bacteria
and their toxins) into the circulation,
potent host responses such as septi-
caemia are not common events during
helminth infections. We found that
FhHDM-1 binds directly to E. coli
lipopolysaccharide (LPS) preventing its
interaction with the TLR4/MD2/CD14
complex on the macrophage surface
(Robinson et al., 2011). FhHDM-
1 also exhibited a striking ability to
protect mice against LPS-induced inflam-
mation by preventing the release of
inflammatory mediators (TNF and IL-
1β) from macrophages (Robinson et al.,
2011).
IFNγ is one of the key cytokines in
the innate immune response to intracel-
lular pathogens, and augments cellular
responses to TLR ligands such as bac-
terial LPS (Held et al., 1999; Schroder
et al., 2006). We also found that, like
the mammalian peptides LL-37, CRAMP,
SMAP-29, and BMAP-28, HDMs signif-
icantly inhibited macrophage TNF pro-
duction in response to combined stim-
ulation with LPS and IFNγ (Thivierge
et al., 2013). Both AMPs/HDPs and HDMs
can seemingly also inhibit inflammatory
macrophages using mechanisms that are
independent of direct binding to LPS
(Brown et al., 2011; Thivierge et al., 2013).
Thus, the secretion of HDMs by the par-
asite may protect the host against exces-
sive bacterial-induced inflammation that
would otherwise occur during migration
of the parasite through the host intesti-
nal wall due to concurrent translocation
of luminal bacteria. By offering this pro-
tection the parasite enhances the sur-
vival of its host and, accordingly, its own
longevity.
Confocal microscopy, using fluores-
cently labeled peptides, has shown that
after initial interaction with lipid rafts
on the macrophage surface, FhHDM-1
enters the cell via the endolysosomal path-
way (Robinson et al., 2012). FhHDM-1
is cleaved by endogenous (host) cathep-
sin L to specifically release a C-terminal
peptide (containing the conserved HDM
amphipathic helix) which then prevents
the acidification of the endolysosomal
compartments by inhibiting vacuolar (v)
ATPase activity. Uncoupling endolysoso-
mal acidification impedes macrophage
antigen processing by proteases, such
as cathepsin L, preventing the presen-
tation of peptides at the cell surface
in conjunction with MHC class II to
CD4 + T cells (Robinson et al., 2012).
By suppressing the antigen presenting
function of host macrophages, HDM
indirectly impairs the subsequent devel-
opment of adaptive immune responses
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against the parasite. However, by alter-
ing the secretion of immunoglobulins
from activated B cells, HDMs are also
capable of directly influencing the host
adaptive response. HDMs enhanced the
IL-4 induced production of IgG1 and sup-
pressed the release of IgG2a from murine
B cells in response to IFNγ (Thivierge
et al., 2013). This is consistent with a
wound healing scenario (Nishio et al.,
2009) which, again, may serve to pro-
tect the host from helminth-induced tissue
damage.
PARASITE-DESIGNED HDMs MAY
HAVE THERAPEUTIC POTENTIAL
The immune-modulatory properties
of mammalian HDPs, and in partic-
ular their ability to prevent excessive
immunopathology associated with bac-
terial sepsis, has attracted interest in
exploiting these as anti-infectives and
immunotherapeutic agents (Easton et al.,
2009). However, their clinical devel-
opment has been hampered by the
occurrence of toxic off-target effects
and cell lysis. Efforts to improve deliv-
ery of HDPs to their desired site of
action (e.g., by conjugation with tar-
geting moieties) are on-going with the
aim of enhancing efficacy whilst reduc-
ing deleterious side effects (Devocelle,
2012). However, helminth-derived HDMs
may represent a more attractive thera-
peutic option: they show all the potent
immunomodulatory effects of the HDPs
without the cytotoxic and cytolytic effects
(Thivierge et al., 2013). We are cur-
rently determining the translatability
of the immune-modulatory effect of
HDMs from murine to human cells rather
than screening an array of animal mod-
els of disease (Robinson et al., 2013)
and we are hopeful that the therapeu-
tic potential of these parasite-designed
molecules can be realised (Donnelly et al.,
2011).
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